Ucb UCB.BE | BRUSSELS Exch | Medical-Diversified | MktCap €39.29B Sales €6.85B | Shares 195M Float 99M

3225599999 ucb.com Brussels, BELGIUM Inc 1925 MGMT owns --
EPS Rank 77

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium. LESS

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024
EPS EUR	2.88	3.99	4.20	4.23	3.87	5.60	2.20	1.81	5.61
CASH FLOW/SHR EUR	1.85	4.64	5.44	4.40	5.20	7.67	5.36	3.16	5.56
PRETAX MARGIN %	18%	22%	22%	20%	16%	21%	9%	8%	19%
RETURN ON EQUITY %	10%	13%	13%	12%	10%	14%	5%	4%	11%
SALES % CHANGE	7%	9%	2%	6%	9%	8%	-5%	-5%	17%
SALES (MIL) EUR	4,147	4,530	4,632	4,913	5,347	5,777	5,517	5,252	6,152
WEEKLY	**Jul 11**	**Jul 18**	**Jul 25**	**Aug 1**	**Aug 8**	**Aug 15**	**Aug 22**	**Aug 29**	**Sep 3**
DATAGRAPH RATING	59	66	64	66	64	69	68	70	70
AVG DAILY VOL (000)	235	221	216	227	211	203	203	197	189
UP DOWN VOLUME	1.3	1.6	1.6	1.8	1.5	1.4	1.5	1.7	1.4
ACCUM/DIST RATING	21	24	31	34	33	31	36	29	30
RELATIVE STRENGTH	70	77	64	63	64	80	78	82	84
GROUP RANK	43	41	39	30	29	23	22	19	19

2025 Estimate	2026 Estimate
7.22 29%	9.83 36%

Earnings Growth Rate	Sales Growth Rate
2023-25 25% (69 Stability)	5%
2021-25 -7% (65 Stability)	3%

COMP RATING 97 SMR RATING A
INV T/O 1.7x 38

DEBT %	2022-24	29%	33%	30%
TAX RATE	2022-24	18%	22%	8%
BACKLOG	2022-24	--	--	--

R & D 28.90% BK VAL 3.83x '24
DIV EUR 0.97 (0.5%) DIV GR RT+2% (0)
BETA 1.54(43.00) ALPHA 0.02 (0.01)
2024 EMPLOYEES 9,378 (3%)

Europe Long +6.06% in 4.9 WKS

OH -2%

LOG (Fixed) PRICE

EPS 25 x

202.00 EUR
+2.15 +1.08%

84
B+

LOG VOLUME

2M
-26%
437.0K

FINANCIALS	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25
EPS (EUR)		3.02		2.58		2.10		0.10		1.64		0.17		1.10		4.51		2.50		3.77e
EPS % CHANGE		+57%		+32%		-30%		-96%		-22%		+70%		-33%		+2,553%		+127%		-16%e
SALES (MIL EUR)		2,778.0		2,999.0		2,925.0		2,592.0		2,589.0		2,663.0		2,791.0		3,361.0		3,487.0		3,708.3e
SALES % CHANGE		+7%		+9%		+5%		-14%		-11%		+3%		+8%		+26%		+25%		+10%e
EPS % SURPRISE		+11.5%		+17.2%		-16.4%		+61.6%		+55.9%		+16.4%		+18.6%		+10.6%		+6.8%		
FUNDS	1,368	1,378	1,391	1,391	1,469	1,580	1,414	1,402	1,389	1,387	1,432	1,465	1,473	1,591	1,698	1,828	1,827	1,837		
SHARES HELD BY FUNDS	53M	55M	55M	57M	56M	55M	54M	54M	53M	53M	54M	53M	58M	61M	62M	62M	60M	58M		

P/E	29
2025 Est.:	28.0
2026 Est.:	20.6
5-yr High:	111
5-yr Low:	15
vs Ind. Avg:	1.2x